AACR Conference Coverage
(Penn LDI) Apr 18, 2018 - Spending on cancer drugs in the United States has nearly doubled in the past five years and continues to grow, imposing substantial financial burden on patients with cancer. One of the biggest drivers of this growth is targeted cancer drugs.
(BMS) Apr 16, 2018 - Patients treated with Opdivo experienced a 32% reduction in the risk of death after two years minimum follow-up; Opdivo remains the only PD-1 inhibitor to demonstrate statistically significant OS versus standard chemotherapy in the primary analysis of a Phase 3 trial in these patients, with benefit maintained with...
There are no AACR Conference Coverage OBR Green articles.